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the course of a fractionated radiotherapy treatment or during 
a PET study. This work examines how transient perfusion of 
vessels may influence tissue radiosensitivity (including 
reoxygenation) and FMISO image contrast, as a guide for dose 
painting. 
 
Material and Methods: Microscopic oxygen and FMISO 
distributions are simulated in tissue using bespoke MATLAB 
software which solves coupled partial differential equations 
by finite difference methods. Dynamic vasculature is 
modelled by opening and closing individual vessels at 
random, with time spent in each state sampled from a 
normal distribution. Oxygen enhancement ratios are 
calculated from the resulting PO2 maps. The optimal 
prescription dose is found by simulating a range of dose 
levels and determining radiobiological cell kill using the 
linear-quadratic model with repopulation. A novel approach 
to modelling reoxygenation is adopted in which a tissue’s 
oxygen consumption in one fraction is reduced by the cell kill 
in previous fractions. 
 
Results: Predicted FMISO tissue-to-muscle ratios (TMR) are in 
the range 1.0-2.3, increasing as PO2 decreases to a peak at 
~7 mmHg. At very low vascularity, FMISO uptake is limited by 
perfusion of tracer into the tissue, rather than the oxygen-
dependent binding characteristic. No gross differences are 
observed in TMRs simulated with static or dynamic vascular 
models. For a representative hypoxic tumour (10 mmHg, 
intrinsic α=0.3) surviving fractions of 10^-9 are predicted at 
doses of: 110 Gy (static vasculature, no reoxygenation), 87 
Gy (dynamic vasculature changing every fraction) and 71 Gy 
(reoxygenation by reduced consumption). The effect of 
vessel dynamics is negligible if significant reoxygenation of 
chronic hypoxia occurs. 
 
 
 
 
 
Conclusion: A model has been demonstrated that predicts 
realistic FMISO uptake in hypoxic tissue and provides a 
method for calculating prescription doses with 
reoxygenation. Individual vessel dynamics do not affect 
FMISO image contrast at 4 hours, or the prescription dose if 
global reoxygenation occurs. 
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Purpose or Objective: With a 5-year survival rate of 5%, 
pancreatic ductal adenocarcinoma (PDAC) is considered a 
disease of unmet-need. Preclinical radiobiological research in 
PDAC has been limited by mouse models that do not 
recapitulate the human biology and, more importantly, the 
immense technical challenges in establishing a platform that 
enables precise irradiation of pancreatic tumours in mice 
 
Material and Methods: Herein we describe the key steps in 
the development of a state-of-the-art preclinical image-
guided radiotherapy (IGRT) platform that enables precise 
planning and dose delivery in the KRASLSL.G12D/+; 
p53R172H/+; PdxCretg/+ (KPC), a genetically-engineered 
mouse model (GEMM) of PDAC. CT (x-ray computerised 
tomography) does not provide the soft tissue contrast 
required for accurate and precise RT planning in the mouse. 
We demonstrate the use of magnetic resonance Imaging (MRI) 
for RT planning in the mouse abdomen. KPC mice with 
spontaneous pancreatic tumours were anaesthetised and 
placed in an MR-CT compatible cradle. A newly-developed 
respiratory-gated multiple echo contrast scan (8 echoes, TE 
6-50 ms) operating at constant TR=3600, was run at 
150x150x300 um resolution in a scan time of ca. 9 minutes. 
 
Results: Tumours were undetectable using CT but showed as 
bright regions on T2-weighted images, as described 
previously. After registration of the MRI to the CT images RT 
planning was quite straightforward and beam trajectory and 
RT dose estimations were performed for a conical arc 
trajectory. MRI can be used with CT-guided RT system to give 
soft tissue contrast and enable RT planning. The respiratory 
gated T2-weighted scans acquired using multiple echoes gave 
very good contrast, though the scan time was relatively long 
(ca. 9 minutes). At the expense of SNR this can be reduced to 
ca. 2 minutes through use of fast spin echo. The different 
steps will be discussed in detail. Precise beam delivery was 
confirmed using immunohistochemical staining for γH2AX 
foci. 
 
Conclusion: Altogether, our IGRT platform represents a novel 
tool to explore the effects of RT on the biology of PDAC and 
investigate the mechanisms of treatment resistance. To our 
best of knowledge, no studies to date have reported such a 
precise MR-based IGRT platform for preclinical 
radiobiological research in the KPC model. This platform will 
enable exploration of the mechanisms of treatment 
resistance and is expected to provide important 
radiobiological insight to guide successful future clinical trials 
that will directly benefit patients with PDAC. 
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Purpose or Objective: MRI is increasingly used in radiation 
oncology for target delineation and real-time treatment 
guidance. The gadolinium-based nanoparticles (GdNP) used in 
this study are a dual modality probe with MRI contrast and 
radiosensitization properties. We use a mouse model of 
pancreatic cancer to demonstrate in vivo contrast 
enhancement, quantification of GdNP concentration, and 
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significant improvement in survival. By modeling our 
preclinical study on current clinic workflows, we show clear 
compatibility with modern patient care, thus heightening the 
translational significance. 
 
Material and Methods: AGuIX (Nano-H, Lyon, France) is a 
gadolinium-based nanoparticle that has been proposed for an 
upcoming clinical trial. We performed in vitro cell uptake and 
radiosensitization studies of a pancreatic cancer cell line in 
preclinical (220kVp) and clinical (6 MV and 6 MV FFF) beams. 
MRI was used to monitor tumor uptake and biodistribution. 
Due to their small size (2-3 nm), the GdNP have good renal 
clearance and long blood circulation (around 20-30 min in 
mice). 
In vivo radiation therapy studies were performed to 
characterize the effect of AGuIX as a radiosensitizer 
(n=8/cohort). Histology was performed to measure the 
increase in damage in the tumor and to evaluate the toxicity 
in healthy tissues.  
 
Results: The in vitro results demonstrate a dose 
enhancement factor (DEF) of 1.37 (p<0.005) when the 
combination of irradiation and GdNP is used with the 220kV 
and a DEF of 1.26 for the clinical 6MV FFF. The maximum 
tumor uptake and tumor/muscle ratio is reached 15 minutes 
after IV injection. The in vivo results demonstrated 
statistically significant tumor regression (P<0.001) and 
increase in median survival (p<0.005) for AGuIX combined 
with radiation vs. radiation alone. There was no observed 
increase in toxicity in the surrounding healthy organs. 
 
 
 
Conclusion: MRI contrast and radiosensitization have been 
demonstrated in a preclinical pancreatic tumor model. There 
is a strong translational potential for AGuIX with modern and 
likely future MRI-guided radiation therapy procedures 
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Purpose or Objective: The value of healthcare can be 
defined as the additional health outcomes gained for each 
euro spent. Thus, understanding costs, and their origins, of a 
medical intervention is key to the estimation of value. 
Costing studies to date have yielded highly variable results 
largely due to which and how resources have been analyzed. 
A rigorous health economics approach requires the cost of 
the real resources used to be identified (ISPOR, 2007). We 
report on such an approach to the estimation of the cost of 
radiation therapy. 
 
Material and Methods: A Time-Driven Activity Based Costing 
(TDABC) model was created for external photon beam 
radiotherapy at the national level. The model was developed 
in an iterative manner by a panel of experts, taking into 
account current knowledge of resources, products, and 
clinical processes. The resources were identified through a 
systematic review of the literature from 1981 to 2015. In 
TDABC, resource unit costs per minute are defined as the 
ratio of gross expense to available capacity. The products, 
defined as courses of treatment for specific tumor 
indications, were derived from the decision trees developed 
by the Collaboration for Cancer Outcomes, Research and 
Evaluation (CCORE). The process map was derived from that 
developed by the AAPM (2012, Ford). 
 
Results: Resources are organized in 3 categories: personnel, 
equipment and overhead. Products are grouped per organ 
site and target volume. For each of these, treatment 
complexity and diversity are addressed by extending the 
AAPM process map in three ways:  
1. six technique categories, specified as follows: single-field, 
2D-RT, 3D-CRT, IMRT, rotational IMRT and stereotactic 
techniques;  
2. eight possible fractionation schedules can be defined;  
3. some steps along the patient care pathway are identified 
separately from the 7 high level steps, see figure.  
These, reflecting an additional level of treatment 
complexity, are optional and hence not necessarily applicable 
to all treatment courses. 
The core input required is the time of personnel’s 
involvement at each process step for every technique and 
product. This TDABC approach yields two classes of output:  
1. costs, at the level of the resources, activities and 
products, the latter being the sum of the costs of the 
component process steps; and  
2. resource utilization efficiency. 
 
Fig1. HERO Process map 
 
 
Conclusion: A TDABC model for external photon beam 
radiotherapy is developed for use at the national level. In the 
next step, the model is being tested in close collaboration 
with selected European Radiotherapy Societies, by 
introducing nation-specific data on the resources consumed, 
monetary values and resources’ time devoted to each step, 
reflecting complexity. These data generate national cost 
estimates per course for a range of radiotherapy treatments. 
The cost estimates and details of the methodology will be 
presented. 
 
